Holger Weis - 02 Jul 2025 Form 4 Insider Report for Alaunos Therapeutics, Inc. (TCRT)

Role
Chief Executive Officer, Director
Signature
/s/ Melinda Lackey, Attorney-in-Fact
Issuer symbol
TCRT
Transactions as of
02 Jul 2025
Transactions value $
$0
Form type
4
Filing time
07 Jul 2025, 19:08:25 UTC
Previous filing
15 Apr 2025
Next filing
20 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Weis Holger Chief Executive Officer, Director C/O ALAUNOS THERAPEUTICS, INC., 2617 BISSONNET ST, SUITE 233, HOUSTON /s/ Melinda Lackey, Attorney-in-Fact 07 Jul 2025 0001846984

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRT Employee Stock Option (right to buy) Award $0 +130,000 $0 130,000 02 Jul 2025 Common Stock 130,000 $5.02 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this grant will vest and become exercisable immediately upon grant and the remaining balance shall vest in substantially equal quarterly installments over a three year period commencing on the Start Date with the first vesting date being October 2, 2025, subject to holder's continuous employment through each vesting date. This option grant shall be subject to the terms and conditions of the Company's 2020 Equity Incentive Plan and a Stock Option Agreement.